Stephen M Ansell1. 1. Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Abstract
PURPOSE OF REVIEW: The purpose of this article is to discuss the tumor microenvironment in lymphoma, and to review potential immune targets that are now becoming relevant because of clinical responses seen with the use of immune checkpoint inhibitors. RECENT FINDINGS: Recent data have shown that cells within the immune microenvironment in lymphoma express programmed death ligand-1 (PD-L1) and many of the intratumoral T cells with an exhausted immune phenotype express programmed cell death-1 (PD-1). This provides a novel opportunity to inhibit the immune checkpoints and initial clinical trials utilizing antibodies that block the interaction between PD-1 and PD-L1 have demonstrated significant clinical responses in various lymphomas, including Hodgkin lymphoma. SUMMARY: The use of immune checkpoint inhibitors, including nivolumab and pembrolizumab, in relapsed and refractory patients with lymphoma is proving highly successful. Patients with Hodgkin lymphoma, in particular, have a very high response rate to PD-1 blockade and responses in these patients appear durable.
PURPOSE OF REVIEW: The purpose of this article is to discuss the tumor microenvironment in lymphoma, and to review potential immune targets that are now becoming relevant because of clinical responses seen with the use of immune checkpoint inhibitors. RECENT FINDINGS: Recent data have shown that cells within the immune microenvironment in lymphoma express programmed death ligand-1 (PD-L1) and many of the intratumoral T cells with an exhausted immune phenotype express programmed cell death-1 (PD-1). This provides a novel opportunity to inhibit the immune checkpoints and initial clinical trials utilizing antibodies that block the interaction between PD-1 and PD-L1 have demonstrated significant clinical responses in various lymphomas, including Hodgkin lymphoma. SUMMARY: The use of immune checkpoint inhibitors, including nivolumab and pembrolizumab, in relapsed and refractory patients with lymphoma is proving highly successful. Patients with Hodgkin lymphoma, in particular, have a very high response rate to PD-1 blockade and responses in these patients appear durable.
Authors: Paolo Anderlini; Rima M Saliba; Celina Ledesma; Tamera Plair; Amin M Alousi; Chitra M Hosing; Issa F Khouri; Yago Nieto; Uday R Popat; Elizabeth J Shpall; Michelle A Fanale; Frederick B Hagemeister; Yasuhiro Oki; Saatva Neelapu; Jorge E Romaguera; Anas Younes; Richard E Champlin Journal: Biol Blood Marrow Transplant Date: 2016-04-06 Impact factor: 5.742
Authors: Catherine S Diefenbach; Fangxin Hong; Richard F Ambinder; Jonathon B Cohen; Michael J Robertson; Kevin A David; Ranjana H Advani; Timothy S Fenske; Stefan K Barta; Neil D Palmisiano; Jakub Svoboda; David S Morgan; Reem Karmali; Elad Sharon; Howard Streicher; Brad S Kahl; Stephen M Ansell Journal: Lancet Haematol Date: 2020-09 Impact factor: 18.959
Authors: Zhihui Song; Wei Wei; Wenming Xiao; Essel D Al-Saleem; Reza Nejati; Liqi Chen; Jiejing Yin; Joseph Fabrizio; Michael N Petrus; Thomas A Waldmann; Yibin Yang Journal: Proc Natl Acad Sci U S A Date: 2020-11-02 Impact factor: 12.779
Authors: A Rueda Domínguez; J Alfaro Lizaso; L de la Cruz Merino; J Gumá I Padró; C Quero Blanco; J Gómez Codina; M Llanos Muñoz; N Martinez Banaclocha; D Rodriguez Abreu; M Provencio Pulla Journal: Clin Transl Oncol Date: 2015-10-26 Impact factor: 3.405
Authors: Annika Nelde; Juliane Sarah Walz; Daniel Johannes Kowalewski; Heiko Schuster; Olaf-Oliver Wolz; Janet Kerstin Peper; Yamel Cardona Gloria; Anton W Langerak; Alice F Muggen; Rainer Claus; Irina Bonzheim; Falko Fend; Helmut Rainer Salih; Lothar Kanz; Hans-Georg Rammensee; Stefan Stevanović; Alexander N R Weber Journal: Oncoimmunology Date: 2016-12-23 Impact factor: 8.110